Resampling phase III data to assess phase II trial designs and endpoints (Q34144413)

31 July 2017

title

Resampling phase III data to assess phase II trial designs and endpoints (English)

1 reference

31 July 2017

main subject

phase III clinical trial

0 references

phase II clinical trial

0 references

7

Mark J Ratain

1 reference

31 July 2017

Manish R Sharma

1

1 reference

31 July 2017

Theodore G Karrison

2

1 reference

31 July 2017

Yuyan Jin

3

1 reference

31 July 2017

Robert R Bies

4

1 reference

31 July 2017

Michael L Maitland

5

1 reference

31 July 2017

Walter M Stadler

6

1 reference

31 July 2017

language of work or name

English

0 references

publication date

27 January 2012

1 reference

31 July 2017

published in

Clinical Cancer Research

1 reference

31 July 2017

volume

18

1 reference

31 July 2017

issue

8

1 reference

31 July 2017

page(s)

2309-2315

1 reference

Comparison of continuous versus categorical tumor measurement-based metrics to predict overall survival in cancer treatment trials

31 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3328614

Prognostic factors and predictive models in renal cell carcinoma: a contemporary review

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3328614

Randomized phase II trials: a long-term investment with promising returns

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3328614

Analysis of the Yield of Phase II Combination Therapy Trials in Medical Oncology

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3328614

The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3328614

Comparison of error rates in single-arm versus randomized phase II cancer clinical trials

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3328614

Elucidation of relationship between tumor size and survival in non-small-cell lung cancer patients can aid early decision making in clinical drug development

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3328614

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3328614

Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3328614

Sorafenib in advanced clear-cell renal-cell carcinoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3328614

Economics of new oncology drug development

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3328614

A two-stage design for randomized trials with binary outcomes.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3328614

Optimal two-stage designs for phase II clinical trials

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3328614

Analysis of tumor burden versus progression-free survival for Phase II decision making.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3328614

Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3328614

Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3328614

Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise?

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3328614

Testing the wrong hypothesis in phase II oncology trials: there is a better alternative

28 October 2018

1 reference

12 December 2020

Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941

1 reference

12 December 2020

Phase II trials in journal of clinical oncology

1 reference

12 December 2020

Randomized phase II trials: inevitable or inadvisable?

1 reference

12 December 2020

Phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other medical specialties

1 reference

12 December 2020

Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels

1 reference

12 December 2020

An alternative model for the evaluation of antitumor activity

1 reference

12 December 2020

Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST

1 reference

12 December 2020

10.1158/1078-0432.CCR-11-1815

Identifiers

DOI

1 reference

31 July 2017

1 reference

31 July 2017

1 reference